Pegcetacoplan Shows Increasing Benefit Over 5 Years in Geographic Atrophy
Overview
Five-year data from the GALE extension study demonstrate that pegcetacoplan treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) results in progressive retinal tissue preservation. Early and continuous treatment leads to greater benefit, with a consistent safety profile observed over the study duration.
Background
Geographic atrophy (GA) is a late-stage manifestation of age-related macular degeneration characterized by progressive loss of retinal tissue and vision. Pegcetacoplan, a complement C3 inhibitor, has been evaluated in the OAKS and DERBY phase 3 trials and the GALE open-label extension to assess its efficacy in slowing GA lesion growth. The GALE study provides the longest clinical data available, with up to 5 years of continuous treatment. Understanding long-term efficacy and safety is critical for managing this chronic, progressive condition.
Data Highlights
| Parameter | Monthly Pegcetacoplan | Every-Other-Month Pegcetacoplan | Projected Sham |
|---|---|---|---|
| GA Growth Reduction (0-24 months) | 19% | 18% | Reference |
| GA Growth Reduction (24-60 months) | 27% | 26% | Reference |
| Overall GA Growth Reduction (0-60 months) | 24% | 23% | Reference |
| GA Growth Reduction in Nonsubfoveal Patients (0-24 months) | 27% | 24% | Reference |
| GA Growth Reduction in Nonsubfoveal Patients (24-60 months) | 33% | 30% | Reference |
| Overall GA Growth Reduction in Nonsubfoveal Patients (0-60 months) | 31% | 27% | Reference |
| Retinal Tissue Preserved (5 years, continuous treatment) | 3.9 mm2 (~1.5 disc areas) | ||
| Retinal Tissue Preserved (5 years, crossover from sham) | 1.9 mm2 | ||
| Infectious Endophthalmitis Rate | 0.04% | ||
| Intraocular Inflammation Rate | 0.24% | ||
| Ischemic Optic Neuropathy Rate | 0.02% | ||
Key Findings
- Pegcetacoplan treatment reduced GA lesion growth by approximately 24% over 5 years compared to projected sham.
- Greater reductions in GA growth were observed in nonsubfoveal patients, with up to 31% reduction over 5 years.
- Continuous treatment for 5 years preserved 3.9 mm2 of retinal tissue, roughly 1.5 optic disc areas.
- Patients initiating treatment earlier preserved twice as much retinal tissue compared to those crossing over from sham at 24 months.
- Tissue preservation translated to approximately 1.5 years of disease progression saved by 60 months.
- The safety profile remained consistent with low rates of mild to moderate adverse events, including infectious endophthalmitis (0.04%) and intraocular inflammation (0.24%).
Clinical Implications
These findings support the use of pegcetacoplan as a long-term treatment option for GA secondary to AMD, emphasizing the importance of early and continuous therapy to maximize retinal tissue preservation. The consistent safety profile over 5 years provides reassurance for clinicians managing this elderly patient population. Treatment can meaningfully delay disease progression, potentially improving patient quality of life.
Conclusion
Pegcetacoplan demonstrates sustained and increasing benefit in slowing GA progression over 5 years, with early initiation yielding greater retinal preservation and a favorable safety profile. This positions pegcetacoplan as a valuable therapeutic option in managing geographic atrophy.
Related Resources & Content
- Dhoot DS, 2026 Macula Society -- Pegcetacoplan Data Show Increasing Benefit Over 5 Years
- Sunness JS et al., 2007 -- The long-term natural history of geographic atrophy from age-related macular degeneration
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.